LENSAR, Inc. (LNSR)
NASDAQ: LNSR · Real-Time Price · USD
14.11
-0.02 (-0.11%)
Apr 1, 2025, 10:19 AM EDT - Market open
Company Description
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.
The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room.
LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR, Inc.
Country | United States |
Founded | 2004 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 140 |
CEO | Nicholas Curtis |
Contact Details
Address: 2800 Discovery Drive Orlando, Florida 32826 United States | |
Phone | 888 536 7271 |
Website | lensar.com |
Stock Details
Ticker Symbol | LNSR |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001320350 |
CUSIP Number | 52634L108 |
ISIN Number | US52634L1089 |
Employer ID | 32-0125724 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Nicholas T. Curtis | President, Chief Executive Officer and Director |
Thomas R. Staab II, CPA | Chief Financial Officer and Secretary |
Alan B. Connaughton | Chief Operating Officer |
Kendra W. Wong | Principal Accounting Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 25, 2025 | SCHEDULE 13D/A | Filing |
Mar 24, 2025 | DFAN14A | Filing |
Mar 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Mar 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Mar 24, 2025 | 8-K | Current Report |
Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 27, 2025 | 10-K | Annual Report |
Feb 27, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |